Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Yan Moore, M.D., as Chief Medical Officer. Dr. Moore has extensive management, research, translational drug development and medical affairs experience across various pharmaceutical and biotechnology companies.
Click here to view original post